GNI Group updates 2025 outlook amid tariff concerns
GNI Group (TSE:2160) has issued an update on its financial forecast for the fiscal year ending December 2025, factoring in the effects of recently announced US tariff policies. The company maintains strong growth expectations for its pharmaceutical segment, projecting revenue of JPY20,202 million and operating income of JPY4,640 million. The drug discovery segment anticipates revenue of JPY955 million and operating income of JPY3,982 million. The medical technology segment faces challenges, with potential operating profit reductions of JPY9 million to JPY15 million depending on tariff rates imposed on goods imported from China. The "Other" segment anticipates revenue of JPY1,525 million and operating income of JPY16,314 million due to listing gains of Cullgen.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Gni Group publishes news
Free account required • Unsubscribe anytime